Vor Biopharma Inc
VOR31.230USD
-0.490-1.54%
收盤 10/10, 16:00（美東）報價延遲15分鐘
196.20M總市值
虧損本益比TTM
關於 Vor Biopharma Inc 公司
Vor Biopharma Inc. 是一家臨牀階段的細胞和基因組工程治療公司。該公司致力於將新型患者工程方法與靶向療法相結合，爲患有血液系統惡性腫瘤的患者提供解決方案。其專有平臺利用造血幹細胞 (HSC) 生物學、基因組工程和靶向療法開發方面的專業知識，對 HSC 進行基因改造，以去除癌細胞表達的表面靶標。該公司的主要工程造血幹細胞 (eHSC) 候選產品包括 tremtelectogene empogeditemcel (trem-cel)，用於治療急性髓系白血病 (AML) 和其他血癌。它旨在取代患有急性髓系白血病 (AML) 和其他血癌的患者的移植標準護理。其 VBP101 是一項 I/II 期多中心、開放標籤、首次在 AML 患者身上進行的 trem-cel 研究。
Vor Biopharma Inc簡介
公司代碼VOR
公司名稱Vor Biopharma Inc
上市日期Feb 05, 2021
CEODr. Jean-Paul Kress, M.D.
員工數量159
證券類型Ordinary Share
年結日Feb 05
公司地址100 Cambridgepark Drive
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02140
電話16176556580
網址https://www.vorbio.com/
公司代碼VOR
上市日期Feb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Vor Biopharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Sarah Reed
Ms. Sarah Reed
Independent Director
Independent Director
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月30日 週二
更新時間: 9月30日 週二
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
28.98%
Reprogrammed Interchange LLC
23.96%
5AM Ventures
3.23%
Fidelity Management & Research Company LLC
1.47%
The Vanguard Group, Inc.
1.40%
其他
40.96%
持股股東
持股股東
佔比
RA Capital Management, LP
28.98%
Reprogrammed Interchange LLC
23.96%
5AM Ventures
3.23%
Fidelity Management & Research Company LLC
1.47%
The Vanguard Group, Inc.
1.40%
其他
40.96%
股東類型
持股股東
佔比
Venture Capital
33.39%
Corporation
23.23%
Investment Advisor
5.08%
Hedge Fund
0.91%
Research Firm
0.66%
Investment Advisor/Hedge Fund
0.62%
Individual Investor
0.33%
Bank and Trust
0.13%
其他
35.65%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
154
2.79M
40.81%
-1.01M
2025Q2
165
100.29M
80.27%
+23.22M
2025Q1
174
100.82M
80.73%
+21.38M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
1.98M
28.98%
-1.00
-0.00%
Sep 19, 2025
Reprogrammed Interchange LLC
1.64M
23.96%
-205.17K
-11.12%
Sep 16, 2025
5AM Ventures
221.14K
3.23%
-96.94K
-30.48%
Jul 08, 2025
Fidelity Management & Research Company LLC
100.79K
1.47%
-216.12K
-68.20%
Jun 30, 2025
The Vanguard Group, Inc.
95.78K
1.4%
-1.23K
-1.27%
Jun 30, 2025
UBS Financial Services, Inc.
67.94K
0.99%
+67.52K
+15961.94%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
53.73K
0.79%
--
--
Jun 30, 2025
Jane Street Capital, L.L.C.
26.28K
0.38%
+16.54K
+169.88%
Jun 30, 2025
Sarissa Capital Management, L.P.
25.40K
0.37%
--
--
Jun 30, 2025
VR Adviser, LLC
25.00K
0.37%
+25.00K
--
Sep 18, 2025
查看更多
持股ETF
更新時間: 10月6日 週一
更新時間: 10月6日 週一
機構名稱
佔比
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
DFA Dimensional US Core Equity Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Russell 2000 ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
